What is Lifesci Capital’s Estimate for CMPX FY2025 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Investment analysts at Lifesci Capital raised their FY2025 earnings per share estimates for Compass Therapeutics in a report released on Tuesday, January 6th. Lifesci Capital analyst C. Zhu now expects that the company will post earnings of ($0.45) per share for the year, up from their previous forecast of ($0.50). Lifesci Capital has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Lifesci Capital also issued estimates for Compass Therapeutics’ Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.46) EPS.

Several other equities research analysts have also recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “overweight” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 price objective on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Tuesday. Leerink Partnrs upgraded shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Finally, Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Stock Down 5.1%

Shares of Compass Therapeutics stock opened at $5.17 on Friday. The business has a fifty day simple moving average of $4.98 and a 200-day simple moving average of $3.90. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $5.86. The firm has a market cap of $919.54 million, a price-to-earnings ratio of -11.49 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.06.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. Vivo Capital LLC raised its position in Compass Therapeutics by 70.0% during the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after buying an additional 2,487,443 shares during the period. Simplicity Wealth LLC grew its stake in Compass Therapeutics by 81.8% during the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock valued at $220,000 after acquiring an additional 38,093 shares in the last quarter. Suvretta Capital Management LLC grew its stake in Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after purchasing an additional 7,592 shares during the period. Finally, CM Management LLC purchased a new stake in shares of Compass Therapeutics in the third quarter worth approximately $525,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.